MLSC Blood decontaminant recieves patent!!!

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks MLSC Blood decontaminant recieves patent!!!

Previous 10 Next 10

To: Mike S who wrote (144)	6/4/1998 4:25:00 PM
From: Cindy Powell	of 196

Hello all, In order that the following press release can be understood in context of MLSC's May 10QSB filing, I am posting both the 10QSB and MLSC's latest press release. Press Release Medical Discoveries, Inc. (OTCBB: MLSC) In response to various rumors and activity in the public markets, Medical Discoveries, Inc. (OTCBB: MLSC) disclosed that the Company has been actively engaged in a series of discussions with several entities including: capital investment; establishment of a joint venture, creation of a new operating division, product development and distribution agreements. In addition, the company disclosed that it has recieved another patent on it's proprietary compound MDI-P. The Company announced today the it is in the final process of completing the first two stages of a series of strategic development activities, and anticipates making several difinitive announcements through the filing of SEC Form 8K within the next few days. Medical Discoveries, Inc. is a development stage bio-pharmaceutical company engaged in the research and development of a new generation of liquid chemical Biocides which have anti-bacterial, anti-fungal and anti-viral properties (HIV/AIDS). For additional information and or to request an investor information package, please contact the Company's Department of Investor Relations at (801) 771-0523. May 14, 1998 MEDICAL DISCOVERIES INC (MLSC) Quarterly Report (SEC form 10QSB) MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION. The Company is in the process of establishing a "consumer products" division (MDI Healthcare Systems) as part of its strategy of developing certain aspects of its core technologies for commercialization. MDI recorded its first revenues from its consumer products division for the period from April 1, 1998 to May 15, 1998. MDI reduced its year-to-date general and administrative expense to $112,923 from $161,684 in 1Q1998 compared to 1Q1997 by increased efficiencies in its operations. Funding for on-going operations is discussed in the "Additional Funding is Required" section below. DEVELOPMENT OF NEW/IMPROVED TECHNOLOGY. During the last quarter, the Company has continued to focus its research and development activities to further enhancing its core technologies. Chief among these efforts (which are in the process of patent applications) is the capability of developing a new generation of consumer products utilizing its "electrolyzed saline waters". These variations of the Company's patented core technologies, and resultant commercially viable products, better enable the Company to aggressively pursue new markets outside of its traditional "pharmaceutical research and development operations" with a wide variety of applications. Included among these new target markets are applications in the newly evolving skin care "cosmeceutical" industry, home water purification, and "bottled waters". These new markets represent significant revenue generating opportunities for the Company in the near term, and the Company is presently developing the appropriate infrastructure to aggressively pursue these markets. The Company remains committed to the pursuit of establishing MDI-P as an effective liquid chemical sterilant for the sterilization of surgical instruments, and developing MDI-P as an effective anti-bacterial, anti-viral and anti-fungal pharmaceutical. PLANS TO FORM A NEW CONSUMER PRODUCTS DIVISION. MDI is in the final stages of establislihig a new operating division focused on the commercialization of products targeted at the health and wellness, cosmetic, home water purification systems and "bottled waters" markets. The products to be marketed by this new division will be a combination of proprietary products internally developed as well as unique products sourced from strategic partners located in the United States and certain international markets. STRATEGIC ALLIANCE. MDI has initiated discussions with a privately held company specializing in the research, development, and commercialization of proprietary products in the health care industry. It is anticipated that these discussions will conclude in the establishment of "joint venture" health care company focused on the identification, exploration, validation, development and commercialization of new innovative solutions to existing and newly emerging health care problems and opportunities. MANAGENIENT AND SCIENTIFIC BOARD ADDITIONS. William J. Novick, Jr., Ph.D., Chief Technical Officer was promoted to the position of Vice President, and will serve as an Officer of the Corporation. Osao Sumita, Ph.D., has joined the Company as Sr. Director, Engineering and Technology Development. Dr. Sumita has spent nearly 20 years in research and development in the field of electrolysis and related technologies. Since 1992 he has been president and founder of Coherent Technologies (Tokyo, Japan) a research and development firm specializing in the development of proprietary electrolysis technology systems. Dr. Sumita received his Doctorate from the Tokyo Institute of Technology, Tokyo, Japan, and is the holder of several patents in the field of electrolysis. In this newly created position, Dr. Sumita will be responsible for technology development and related research activities. Mr. Neal G. Ofiesh has recently joined the company as National Sales Director, Consumer Products. Mr. Ofiesh has been actively engaged in the sales, distribution and management of sales activities for a number of companies in the field of water purification systems, cosmetics and related consumer products. In this newly created position, Mr. Ofiesh will provide the Company with proven expertise in establishing a national distribution network for the Company's consumer products. Prior to joining the Company, Mr. Ofiesh was affiliated with the MeLaLeuca, Natural World and NSA corporations. PATENT ACTIVITY. The Company was notified by the US Patent Office that another patent for its MDI-P technology was issued. The patent number is titled "Electrically Hydrolyzed Salines as Microbicides" and is for a microbiocidal solution for in vivo and in vitro treatment of microbial infections. This brings to six the current number of patents issued for the Company's core technologies. Additionally, the Company received notice of allowance of another patent from the US Patent Office for the use of MDI-P "Electrically Hydrolyzed Salines as Microbicides". JAPANESE MARKET OPPORTUNITIES AND ANALYSIS. MDI is continuing discussions regarding licensing and other business development relationships with several Japanese companies. There is strong interest in the medical pharmaceutical market applications of the Company's proprietary compound, MDT-P. MDI is actively discussing potential alliances with several Japanese companies to jointly collaborate in this area using the Company's patented technologies and drawing on its experience in the medical area with its Scientific Advisory Board. In December of 1997, MDI was invited to present an update of its research activities at the annual Functional Water Society Foundation in Tokyo, Japan. Dr. Novick, the Company's Chief Technical Officer, presented the results of the research work of Aldonna Baltch, MD and her colleagues at the Stratton VA Medical Center, Albany, New York. Dr. Baltch's in-vitro research activities have confirmed the effectiveness of MDI-P as an efficient anti-fungal compound through the complete destruction of the fungus Candida Albicans. ADDITIONAL FUNDING IS REQUIRED. MDI needs to raise additional capital to fund its FDA and international regulatory approvals process. Additionally, each of the research and testing programs in progress continues to show promise and generate valuable scientific data, and therefore, requires appropriate levels of funding. Management intends to raise substantial additional funds in private stock offerings in the near future in order to meet its near-term funding requirements with a special emphasis in Japan. In the future, management anticipates the need to raise substantial additional funds in public stock offerings as well. As additional funds are raised, the Company intends to commence paying salaries to its officers. The Company also intends at that time to hire additional technical and administrative personnel. The bulk of any additional funding will likely be spent on continued research, testing, and patent protection with respect to MDI-P. FUNDING. In January 1998, the Company raised $50,000 in exchange for 270,270 shares of common stock at $0.1875 per share and warrants to purchase 540,540 shares of stock at $1.00 per share.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (146)	6/4/1998 11:00:00 PM
From: (no name provided)	of 196

Hi Cindy: Been following mlsc and your thread...keep the info flowing. I read the 10Q you posted and the press release...Just something to add: I met Dr. Bill Novick (CTO and now promoted to VP) awhile ago when he was head of ww prod.dev for Hoechest...he's a real tough as nails scientist type (Duke PhD)...only goes by the book, pure science, hard data, lots of proof before moving to the next step. Frankly when I heard he joined mlsc, I bought, if he sees something in their compounds then I'll bet on him. Looking forward to the 8K (doesn't seem that mlsc would announce in 8K unless it was important...) Stepannick, Ph.D.

Share	RecommendKeepReply Mark as Last Read Read Replies (2)

To: (no name provided) who wrote (147)	6/5/1998 1:03:00 PM
From: Cindy Powell	of 196

Medical Discoveries, Inc., and Advanced Bio-Technologies Establish New 'Cosmeceuticals' Joint Venture Company PR Newswire - June 05, 1998 12:48 MLSC %MTC %JVN %PDT V%PRN P%PRN ------------------------------------------------------------------------ LAYTON, Utah, June 5 /PRNewswire/ -- Medical Discoveries, Inc., (OTC Bulletin Board: MLSC) announced it has agreed in principle with Advanced Bio-Technologies, Inc., to establish a new company, Regenere(TM) Inc., (pronounced "ray jen air", French meaning "to revitalize"). Regenere(TM) will focus on the development and commercialization of a new generation of patented wound care and skin repair "cosmeceuticals" for repairing, restoring and revitalizing damaged skin. Advanced Bio-Technologies, Inc., ("ABT") of Silverdale, Washington is a privately held corporation specializing in the research, development and sales of silicone based wound treatment and related skin care products. The company's flagship product is Kelo-cote(R) a clinically proven silicone topical gel which aids in the rapid healing and reduction of scar tissue resulting from cuts, burns and abrasions, as well as effectively and dramatically reducing the appearance of older scars. Medical Discoveries, Inc., ("MDI") through its Japan and USA based research and development teams, has been developing a new generation of wound cleansing and skin care products based on its proprietary core technologies. MDI and ABT are transferring their existing skin care products into Regenere(TM), Inc., and will focus combined research and product development into additional innovative products for wound healing and skin care. ABT President and CEO, Alvin S. Berlat explained "Kelo-cote(R) is a unique product which protects wounds and promotes rapid healing, and has the proven ability to reduce the appearance of older scars. Unlike "silicone sheeting" products which must be taped over the scar, Kelo-cote(R) is a gel which when applied becomes invisible, allowing the skin to breath while acting as a barrier to waterborne bacteria. Kelo-cote(R) is the only patented product of its type available. The formation of Regenere(TM) enables us to introduce a complete "cosmeceutical system" for wound care and skin repair." "The creation of Regenere(TM) represents a commitment to become the world's leading innovator and supplier of a new generation of "cosmeceuticals" targeted at repairing, restoring and revitalizing damaged skin," stated MDI President and CEO, Lee F. Kulas. "This joint venture brings both MDI and ABT to share technologies, collaborate on scientific research, and energize product development and rapid introduction in the fast growing "cosmeceuticals" marketplace and is the first step of a corporate strategy to move certain aspects of our core technologies into consumer focused, revenue producing, emerging markets, while pursuing FDA approvals on our MDI-P compound targeted at anti-bacterial, anti-fungal and anti-viral (HIV/AIDS) applications." SOURCE Medical Discoveries, Inc. /CONTACT: Press only: Alvin S. Berlat of Advanced Bio-Technologies, Inc., 360-698-2266, or Analysts Only: Marlin Toombs, Director, Investor Relations of Medical Discoveries, Inc., 801-771-0523/ /Web site: mdi-p.com (MLSC)

Share	RecommendKeepReply Mark as Last Read

To: (no name provided) who wrote (147)	6/5/1998 8:37:00 PM
From: Cindy Powell	of 196

Welcome on board Stepannick! I agree with your reasoning that scientists and management of this calliber wouldn't have joined MLSC if they hadn't recognized something compelling, exciting and promising in the MDI-P. Beings how there are literally 100's of uses for the MDI-P and the variations are being promptly secured with patent protection, I think we have a sure-fire winner. I know how excited to get now! Very! :o) Thankyou for your thoughts and information regarding Dr. Bill Novick. I like the line upon line, precept upon precept approach to science also, and Dr. Novick's experience and education with Hoechest and Duke only increases my confidence. It might be interesting to note that the two top Electrolized Water scientists in Japan are also part of MLSC's team. We definitely have a winner here. Best regards, Cindy

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (149)	6/6/1998 1:15:00 AM
From: Dr. Bob	of 196

Greetings Cindy- New here, but very familiar with the MDI team (Salt Lake, Tokyo, and new team in Europe) through my research...how did you learn about the Kubota-sensei and Sumita-sensei "ichiban" status, and their knowledge of the MDI-P compound?...if you check in Japan you can find that they have developed many uses for electrolyzed water, and Sumita-sensei has many patents in this area. Rumor is that he has xfered his patents to MDI as part of "YET ANOTHER" new MDI company (alliance or venture) maybe in agriculture and/or water purification. Let's hope MDI secret stays subrosa for the time being ;) Dr. Bob

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Dr. Bob who wrote (150)	6/8/1998 2:47:00 PM
From: Cindy Powell	of 196

Good afternoon Dr. Bob, I have kept close tabs on Medical discoveries patents, activites and additions to their team for several years now, and have known about the two top Japanese Electrolzed water scientists involvement with Medical Discoveries for a while. Patience and faith in Medical Discoveries team and product is paying off! MLSC has quoted as high as .81 cents today and is still going! The sky is the limit! The fact that the Japanese goverment is following electrolzed water technology so attentively, and is backing research and investigation into this technology monetarily is tell tale, and I believe it will just be a matter of time until the United States and Europe catch on to the merits of this technology. The need for a non toxic, effective and environmentally friendly solution to the toxin problem is seeping into the public awareness arena, and without a doubt the Medical Discoveries team will be first in line to capitolize on what the MDI-P technology has to offer both in terms of being beneficial to mankind and beneficial to us shareholders in terms of investment success. It is so exciting to watch as the Medical Discoveries' plan of action materializes and joint ventures and alliances unfold. Entrance into the bottled water markets, home purification, environmental remediation, agriculture and cosmeceuticals markets provide phenomenal opportunity for growth and revenue, and I know that the team that Medical Discoveries has assembled will make it happen and bring the dreams for MDI-P to fruition. Dr Weil, a harvest trained and educated MD and best selling author of Spontaneous Healing and Eight Weeks to Optimal Health, is presently advocating the installation of home water purification units as one of his top ten ways to "maximize your natural healing power." As more and more research rolls in regarding toxins and the need for individual and consumer responsibilty in keeping the damaging effects of toxins in check, home water purification systems look to becoming mainstream in the not too distant future. Dr Weil advises that drinking only bottled water or installing a home water purification system, and eating organic produce whenever possible, is mandatory for winning the battle against toxins. Dr Weils Hippocrates' approach and ideals for health and healing "First do no Harm..." are well respected and widely followed, and his marriage of the best in conventional and alternative medicine as "integrative medicine" are garnering more and more respect and esteem as the public takes more and more responsiblility in their personal health and wellness, and as physicians suggest that their patients become active participants in their own health and well being through exercise, diet, and being apprised of toxins, free radicals ect. I am soooo excited to see Medical Discoveries aspire to be part of the new integrated medicine movement in health and wellness that is gaining crediblity and the support of more and more mainstream physicians. Dr. Weils advocating bottled water and home water purification systems is a MAJOR plus for Medical Discoveries, and the MDI-P technology will no doubt be the technology of choice for the many applications that these opportunities will afford. But .... (shh!!!) I agree, let's hope that the MDI secret stays subrosa for the time being. :o) Pleasant day and best regards, Cindy

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (151)	6/9/1998 6:30:00 AM
From: KGoodson	of 196

Cindy, Here is the Latest On MLSC...Late PM Yesterday Kerry Medical Discoveries, Inc., Establishes a New Operating Division: MDI HealthCare Systems PR Newswire - June 08, 1998 18:39 MLSC %MTC %HEA V%PRN P%PRN LAYTON, Utah, June 8 /PRNewsire/ -- Medical Discoveries, Inc., (OTC Bulletin Board: MLSC) announced today it has established a new operating division of the company, MDI HeathCare Systems, will focus on the immediate commercialization of new generation of water purification systems for consumer and industrial applications..... Medical Discoveries, Inc., ("MDI") through its Japan and USA based research and development teams, has been actively engaged in sourcing and developing a new generation of consumer targeted water purification machines based on certain patents in electrolysis technology. MDI HeathCare Systems will begin marketing an improved electrolysis water purification system for the consumer market. This new device provides both alkaline water (pH range of 10.0) for drinking, and acidic water (pH range 4.0) for washing fruits and vegetables, and cleansing hands and face. "The creation of MDI HealthCare Systems enables MDI to develop a focused approach toward this new and emerging healthcare market. Water quality is one of the most important aspects of improving and maintaining good health, and the purification and "enhancement" of drinking water utilizing the superior and effective electrolysis technology places MDI in a strong position" stated MDI President and CEO, Lee F. Kulas. "Our increasingly strong intellectual property and proprietary position, coupled with the depth of experience and knowledge of our Japanese and USA based scientific teams have enabled MDI to broaden the scope, fields of interest and market opportunities for our technology. We will continue to expand our horizons and pursue those markets and applications where our technologies provide the opportunities to improve quality of life and offer strong profit potential." The establishment of MDI HealthCare Systems is part of a corporate strategy to move certain aspects of MDI core technologies into consumer focused, revenue producing, emerging markets, while pursuing FDA approvals on our MDI-P compound targeted at anti-bacterial, anti-fungal and anti-viral (HIV/AIDS) applications. SOURCE Medical Discoveries, Inc. /CONTACT: Sales: customer service, 801-771-0523; Press and Analysts Only: Marlin Toombs, Director, Investor Relations of Medical Discoveries, Inc., 801-771-0523/ /Web site: mdi-p.com (MLSC)

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: KGoodson who wrote (152)	6/10/1998 8:59:00 AM
From: Dr. Bob	of 196

Hi KGoodson/Cindy: Just saw another announcement from Medical Discoveries...named a CFO, National Sales Director, Japanese Engineer, and some promotions...things are really popping. What I find intriquing is when I reread the shareholder letters from Kulas it's all there, sort of a roadmap/plan of action, so there really aren't any suprises here just a dream, good planning and thorough execution. (would really love to know what motivated Kulas to get involved in the first place...any idea on his background?, when I reread the 10Qs it doesn't sound like there's been any money for salaries, so why/how did Kulas convince these scientists to join with him?) Anyway...think I'll follow your advice and get some more before it goes over $1.00!... Dr. Bob

Share	RecommendKeepReply Mark as Last Read Read Replies (2)

To: Dr. Bob who wrote (153)	6/10/1998 11:02:00 AM
From: Cindy Powell	of 196

Tuesday June 9, 6:22 pm Eastern Time Company Press Release SOURCE: Medical Discoveries, Inc. Medical Discoveries, Inc. Announces Management Additions, Promotions LAYTON, Utah, June 9 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC - news) focused on the research, development and commercialization of electrolysis based products targeted at anti-bacterial, anti-fungal and anti-viral (HIV/AIDS) applications, announced today the following additions and promotions. Scott R. Wood, CPA has been named Chief Financial Officer. Since 1995, Mr. Wood has served as the Company's Financial Advisor. Mr. Wood received his MBA from Brigham Young University in 1980, and was awarded his Certified Public Accountant Certificate in 1983. Since April of 1997, Mr. Wood has worked closely with MDI's Senior Management team in strategic planning and development, and has been closely involved in the recent joint venture and other business development projects. Neal G. Ofiesh has been named National Sales Director for newly created MDI HealthCare Systems division. Mr. Ofiesh has been actively engaged in the sales, distribution and management of sales activities for a number of companies in the field of water purification systems, cosmetics and related consumer products. In this newly created position, Mr. Ofiesh will provide the Company with proven expertise in establishing a national distribution network for the Company's consumer targeted products. Prior to joining the Company, Mr. Ofiesh was affiliated with the MeLaLeuca, Natural World and NSA corporations. Osao Sumita, Ph.D. has joined MDI Team Japan, as Senior Director Engineering and Technology Development. Dr. Sumita has spent over 20 years in research and development in the field of electrolysis and related technologies. Since 1992 he has been president and founder of Coherent Technologies (Tokyo, Japan) a research and development firm specializing in the development of proprietary electrolysis technology systems. Dr. Sumita received his Doctorate from the Tokyo Institute of Technology, Tokyo, Japan, and is the holder of several patents in the field of electrolysis. In this newly created position, Dr. Sumita will be responsible for technology development and related research activities. William J. Novick, Jr., Ph.D. Chief Technical Officer has been promoted to Vice President and will become an Officer of the Company. Troy Fullmer, Manager Marketing Research, has been promoted to Director of Market Research. ''These additions and promotions strengthens the Company and rewards individuals whose efforts have positioned MDI for growth into revenue producing markets. MDI will pursue those markets and applications where our technologies provide the opportunities to improve quality of life and offer strong profit potential,'' stated President and CEO, Lee F. Kulas. SOURCE: Medical Discoveries, Inc.

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Cindy Powell who wrote (154)	6/11/1998 11:31:00 AM
From: Cindy Powell	of 196

Wednesday June 10, 6:44 pm Eastern Time Company Press Release SOURCE: Medical Discoveries, Inc. Medical Discoveries, Inc. Announces $3.5 Million Capital Investment LAYTON, Utah, June 10 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC - news) announced today that on June 9, 1998, it closed a private placement for a capital investment of up to $3.5 million. The investment consists of staged purchases of common stock and exercise of warrants. The investment is being made by a private financial group consisting of USA based medical doctors representing a variety of specialties. The Company has also granted exclusive limited distribution rights for certain domestic and international markets to this group. The marketing rights are for the Company's own products as well as products from Regenere, Inc., its joint venture with Advanced Bio-Technologies, Inc. ''This particular group is an excellent fit for MDI because the physicians understand our technology, support the research and development, and will be a valuable asset in our distribution and sales activities'', announced President and CEO, Lee F. Kulas. The Company will use these funds to pursue FDA approvals for its MDI-P compound targeted at anti-viral (HIV/AIDS), anti-bacterial, and anti-fungal applications and for business development purposes for the Company's recently announced joint venture opportunities. SOURCE: Medical Discoveries, Inc.

Share	RecommendKeepReply Mark as Last Read